Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 7.6% Higher – What’s Next?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was up 7.6% during mid-day trading on Wednesday . The stock traded as high as $0.26 and last traded at $0.26. Approximately 17,897,355 shares traded hands during mid-day trading, a decline of 70% from the average daily volume of 59,221,816 shares. The stock had previously closed at $0.24.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Friday, January 17th. They set a “hold” rating for the company.

Tonix Pharmaceuticals Stock Performance

The firm has a market capitalization of $71.60 million, a price-to-earnings ratio of -0.01 and a beta of 2.02. The firm’s 50 day simple moving average is $0.27 and its 200 day simple moving average is $0.29. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Sell-side analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 218,003 shares of the company’s stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.